6 October 2020 

Bharat Biotech has partnered with ViroVax to use the latter’s adjuvant to boost the immune response of its Covid-19 vaccine candidate Covaxin. Bharat Biotech will have access to ViroVax’s Alhydroxiquim-II adjuvant technology to support its Covid-19 vaccine candidate, which is currently in Phase II clinical trials.

NVIDIA is creating a supercomputer named Cambridge-1 to enable artificial intelligence (AI)-based research on Covid-19, as well as other healthcare areas. Claimed to be the UK’s most powerful supercomputer, Cambridge-1 will be initially leveraged by GlaxoSmithKline, AstraZeneca, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London and Oxford Nanopore Technologies for pharmaceutical research.

Fred Hutchinson Cancer Research Center has opened the new Covid-19 Clinical Research Center to help assess new interventions for the prevention and treatment of the disease. The new centre will offer a collaborative space for scientists and clinicians to work on Phase I through III clinical trials in participants diagnosed with Covid-19, and other infectious diseases in the future.

Biotechnology startup HDT Bio has completed a $3m seed funding round led by Zoic Capital for the development of its Covid-19 vaccine candidate, HDT-301. In alliance with the US National Institutes of Health, the vaccine is scheduled to begin clinical trials in the fourth quarter of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.